Swiss Medical Devices for Autologous Regenerative Medicine: From Innovation to Clinical Validation

被引:7
|
作者
Gomri, Farid [1 ]
Vischer, Solange [1 ]
Turzi, Antoine [1 ]
Berndt, Sarah [1 ,2 ]
机构
[1] Regen Lab SA, CH-1052 Le Mt Sur Lausanne, Switzerland
[2] Geneva Univ Hosp, Dept Plast Reconstruct & Aesthet Surg, Fac Med, CH-1205 Geneva, Switzerland
关键词
platelet-rich plasma; PRP; tissue regeneration; cell therapy; regenerative medicine; autologous biologics; ortho-biologics; hyaluronic acid; HA; good manufacturing practices; GMP; medical devices; PLATELET-RICH PLASMA; HYALURONIC-ACID; KNEE OSTEOARTHRITIS; GROWTH-FACTORS; CELLS; CLASSIFICATION; MACROPHAGES; LEUKOCYTE; OUTCOMES; RELEASE;
D O I
10.3390/pharmaceutics14081617
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Regenerative medicine, based on the use of autologous tissues and embryonic, stem or differentiated cells, is gaining growing interest. However, their preparation, in a manner compliant with good practices and health regulations, is a technical challenge. The aim of this manuscript is to present the design of reliable CE marked medical devices for the preparation of standardized platelet-rich plasma (PRP) and other autologous biologics intended for therapeutic uses. There are numerous PRP isolation processes. Depending on the methodology used, PRP composition varies greatly in terms of platelet concentration, platelet quality, and level of contamination with red and white blood cells. This variability in PRP composition might affect the clinical outcomes. The devices presented here are based on a specific technology, patented all over the world, that allows the precise separation of blood components as a function of their density using thixotropic separator gels in closed systems. This allows the preparation, in an automated manner, of leukocyte poor PRP with a standardized composition. Production of different forms of PRP is a clinical asset to suit various therapeutic needs. Therefore, we are offering solutions to prepare PRP either in liquid or gel form, and PRP combined with hyaluronic acid. These biologics have been successfully used in many different therapeutic domains, resulting in more than 150 published clinical studies. We also developed the CuteCell technology platform for cell culture expansion for further autologous cell therapies. This technology enables the safe and rapid in vitro expansion of cells intended for therapeutic use in good manufacturing practices (GMP) and autologous conditions, using blood-derived products as culture media supplementation. We summarize in this article our 20 years' experience of research and development for the design of PRP devices and, more recently, for PRP combined with hyaluronic acid.
引用
收藏
页数:24
相关论文
共 50 条
  • [21] Stem cells and regenerative medicine: From research regulation to clinical applications
    Chalmers, Donald
    Rathjen, Peter
    Rathjen, Joy
    Nicol, Dianne
    [J]. JOURNAL OF LAW AND MEDICINE, 2013, 20 (04) : 831 - 844
  • [22] Regenerative medicine research in China: from basic research to clinical practice
    XiaoBing Fu
    [J]. Science China Life Sciences, 2014, 57 : 155 - 156
  • [23] Regenerative medicine research in China:from basic research to clinical practice
    FU XiaoBing
    [J]. Science China(Life Sciences), 2014, 57 (02) - 156
  • [24] Technical and biological review of authorized medical devices for platelets-rich plasma preparation in the field of regenerative medicine
    Magalon, Jeremy
    Brandin, Thibault
    Francois, Pauline
    Degioanni, Clara
    De Maria, Lucille
    Grimaud, Fanny
    Veran, Julie
    Dignat-George, Francoise
    Sabatier, Florence
    [J]. PLATELETS, 2021, 32 (02) : 200 - 208
  • [25] Innovation for Safe and Effective Medical Devices: Contributions From Postmarket Surveillance
    Zippel, Claus
    Bohnet-Joschko, Sabine
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (02) : 237 - 245
  • [26] Innovation for Safe and Effective Medical Devices: Contributions From Postmarket Surveillance
    Claus Zippel
    Sabine Bohnet-Joschko
    [J]. Therapeutic Innovation & Regulatory Science, 2017, 51 : 237 - 245
  • [27] From Validation of Medical Devices towards Validation of Adaptive Cyber-Physical Systems
    Tavcar, Joze
    Duhovnik, Joze
    Horvath, Imre
    [J]. JOURNAL OF INTEGRATED DESIGN & PROCESS SCIENCE, 2019, 23 (01) : 37 - 59
  • [28] "VII International Congress of Biomaterials, BIOMAT' 2018" (14-16 March 2018, Havana, Cuba): from medical devices to regenerative medicine
    Menendez, Tamara
    Veranes-Pantoja, Yaymarilis
    [J]. INTERNATIONAL JOURNAL OF MATERIALS RESEARCH, 2019, 110 (04) : 284 - 285
  • [29] A Framework for In Silico Clinical Trials for Medical Devices Using Concepts From Model Verification, Validation, and Uncertainty Quantification
    Bodner, Jeff
    Kaul, Vikas
    [J]. JOURNAL OF VERIFICATION, VALIDATION AND UNCERTAINTY QUANTIFICATION, 2022, 7 (02):
  • [30] Highlights from the American Medical Society for Sports Medicine position statement on responsible use of regenerative medicine and orthobiologics in sports medicine
    Shapiro, Shane A.
    Finnoff, Jonathan T.
    Awan, Tariq M.
    Borg-Stein, Joanne P.
    Harmon, Kimberly G.
    Herman, Daniel C.
    Malanga, Gerard
    Master, Zubin
    Mautner, Kenneth
    [J]. BRITISH JOURNAL OF SPORTS MEDICINE, 2022, 56 (03)